These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23180880)

  • 1. Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients.
    Krüger T; Brandenburg V; Schlieper G; Marx N; Floege J
    Nephrol Dial Transplant; 2013 Mar; 28(3):534-41. PubMed ID: 23180880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K antagonists: beyond bleeding.
    Krüger T; Floege J
    Semin Dial; 2014; 27(1):37-41. PubMed ID: 24400802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
    Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
    Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulants, renal failure and atrial fibrillation.
    Genovesi S; Santoro A
    Expert Opin Drug Saf; 2013 Jan; 12(1):1-3. PubMed ID: 23163428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
    Guo Y; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Left atrial appendage occlusion as replacement of coumarin anticoagulants in calciphylaxis].
    Andolfatto M; Tangredi M; Vischi M; Pinerolo C; Cereda A; Napodano P; Cozzolino M
    G Ital Nefrol; 2022 Jun; 39(3):. PubMed ID: 35819038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coumarins and survival in incident dialysis patients.
    Knoll F; Sturm G; Lamina C; Zitt E; Lins F; Freistätter O; Kronenberg F; Lhotta K; Neyer U
    Nephrol Dial Transplant; 2012 Jan; 27(1):332-7. PubMed ID: 21771750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antithrombotic management in atrial fibrillation].
    Fauchier L; Taillandier S; Clementy N
    Rev Prat; 2013 Feb; 63(2):199, 201-6. PubMed ID: 23513780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dilemmas in the management of atrial fibrillation in chronic kidney disease.
    Reinecke H; Brand E; Mesters R; Schäbitz WR; Fisher M; Pavenstädt H; Breithardt G
    J Am Soc Nephrol; 2009 Apr; 20(4):705-11. PubMed ID: 19092127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coumarin use in dialysis patients with atrial [corrected] fibrillation: yes, after individual risk stratification.
    Hörl WH
    Nephrol Dial Transplant; 2009 Nov; 24(11):3285-7. PubMed ID: 19666666
    [No Abstract]   [Full Text] [Related]  

  • 17. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy in end-stage renal disease.
    Chunduri S; Folstad JE; Vachharajani TJ
    Hemodial Int; 2017 Oct; 21(4):453-471. PubMed ID: 28544274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.